Regardless of whether your medical team favors escalation or early aggressive treatment, there are a few common principles when prescribing MS treatments. These include the following, according to ...

On June 9, Jan Janisch-Hanzlik became what Nebraska Medicine researchers believe to be the first in the world to receive an experimental treatment for multiple sclerosis.

A study identified a protein that stalls myelin repair in the brain, suggesting that targeting it could be a strategy for MS treatment.

According to Freeman and co-authors, the early aggressive treatment strategy is appropriate for people with relapsing-remitting MS at diagnosis, regardless of the patient's age or disability level.

Today, this trio of drugs is the standard treatment for MS globally, allowing many people to escape the fate that befell Andrea decades ago. I am confident that people whose MS is just beginning can ...

Scientists discovered a genetic marker that predicts before MS therapy whether glatiramer acetate or interferon is likely to ...

Most medicines for treating MS require an injection; however, newer oral medicines, like Vumerity, provide an easier treatment option.

A new drug for people who have one of the worst forms of multiple sclerosis aims to make treatment much easier for patients. Ocrevus is a medicine commonly used to treat primary progressive MS ...

Neuro-immunologist Stephen Hauser, MD, whose maverick thinking transformed the treatment landscape for patients with multiple sclerosis (MS), has received the 2025 Breakthrough Prize in Life Sciences.

New AI model improves MS diagnostics Date: May 1, 2025 Source: Uppsala University Summary: To provide the right treatment for MS, it is important to know when the disease changes from relapsing ...

A Paradigm Shift in MS Treatment Currently, the go-to treatments for relapsing forms of MS are disease-modifying therapies (DMTs).

Six of those nine patients started interferon-beta treatment after being diagnosed with MS, and four of the patients experienced exacerbation of psoriasis during exposure to interferon-beta.